Investment Thesis
AtriCure demonstrates strong product market fit with 14.9% revenue growth and exceptional 77.4% gross margins, but faces critical operational challenges with negative $7.8M free cash flow and interest coverage of only 0.3x. Despite excellent liquidity providing near-term runway, the disconnect between strong gross margins and collapsing profitability, combined with unsustainable cash burn, indicates fundamental business model stress that threatens long-term viability.
Strengths
- Robust revenue growth of 14.9% YoY demonstrates market demand
- Exceptional 77.4% gross margin reflects strong pricing power and manufacturing efficiency
- Fortress balance sheet with 4.29x current ratio and only 0.12x debt/equity ratio
- Strong cash reserves of $146.2M providing operational runway
Risks
- Negative operating cash flow of $4.0M and free cash flow of $7.8M despite positive net income signals severe operational distress
- Interest coverage ratio of 0.3x indicates inability to service $61.0M debt from operating earnings, creating refinancing risk
- Massive 77% gap between 77.4% gross margin and 0.4% operating margin suggests uncontrolled SG&A or operational expenses
- Near-zero profitability (0.1% net margin) leaves no margin for error in competitive medical device market
Key Metrics to Watch
- Operating cash flow trend and path to positive conversion
- Interest coverage ratio improvement toward minimum 1.5x sustainability threshold
- Operating margin expansion to 5-10% range typical for medical device companies
- Working capital dynamics and cash conversion cycle efficiency
Financial Metrics
Revenue
141.2M
Net Income
108.0K
EPS (Diluted)
$0.00
Free Cash Flow
-7.8M
Total Assets
644.0M
Cash
146.2M
Profitability Ratios
Gross Margin
77.4%
Operating Margin
0.4%
Net Margin
0.1%
ROE
0.0%
ROA
0.0%
FCF Margin
-5.6%
Balance Sheet & Liquidity
Current Ratio
4.29x
Quick Ratio
3.18x
Debt/Equity
0.12x
Debt/Assets
23.6%
Interest Coverage
0.31x
Long-term Debt
61.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:05:27.102127 |
Data as of: 2026-03-31 |
Powered by Claude AI